Syntagon CDMO Services

About Nanologica

Nanologica's mission is to make diabetes and obesity medicines available to more patients by providing products that lower manufacturing costs. The company has achieved this through its proprietary NLAB Saga® silica platform, which offers superior performance in preparative chromatography for peptide purification, and has established itself as a public company on Nasdaq Stockholm. Its strategy combines direct sales of its consumables with CDMO services via Syntagon to capture value across the pharmaceutical manufacturing value chain.

Therapeutic Areas